The FDA said it plans to expand the agency’s Focus Areas of Regulatory Science (FARS) to include aging and longevity, signaling a formal push to standardize how interventions in “healthspan” are evaluated. FDA Chief Scientist Steven Kozlowski told the Aging Research & Drug Discovery Meeting at Harvard that the update is expected early in fiscal year 2027. Kozlowski emphasized the need for a pre-competitive, qualified shared endpoint that regulators can accept across trials, enabling feasible study designs and improving accessibility. Acting Chief of Staff Lowell M. Zeta called the move an inflection point for the FDA’s adaptation to rapidly evolving science. For drug developers, the message is that the agency is seeking a common regulatory bridge for aging-related clinical development rather than treating each program as a one-off therapeutic area.